akrasia
Established Member (Voting Rights)
Merged thread
Covid 19 Antibodies
https://www.motherjones.com/politic...coronavirus-antibodies-fade-immunity-vaccine/
Merged thread
Covid 19 Antibodies
https://www.motherjones.com/politic...coronavirus-antibodies-fade-immunity-vaccine/
The observed fall..., I presume.The observed in antibody titres is typical post-infection and not yet a cause for concern.
The observed fall..., I presume.
https://www.jwatch.org/na51986/2020/07/20/characterizing-cognitive-impairment-patients-recoveredCharacterizing Cognitive Impairment in Patients Recovered from COVID-19
Claire Wilcox, MD reviewing Zhou H et al. J Psychiatr Res 2020 Oct
Impairments in selective attention were found in recently recovered patients.
Viral infections (e.g., influenza A, severe acute respiratory syndrome, and Middle East respiratory syndrome) can impair neuropsychiatric function, and inflammation can adversely affect cognitive function. In a study examining the effects of COVID-19 on cognition, 29 otherwise healthy patients in China (age range, 30–64; 18 men) who had recently been hospitalized for COVID-19 and subsequently recovered and 29 age-, education-, and sex-matched healthy controls underwent neuropsychiatric testing (attention and memory, executive function, processing speed, and perceptual abilities).
Recovered COVID-19 patients were tested usually 2 to 3 weeks after admission and after they had two negative nucleic acid tests. During acute infection, COVID-19 patients had tests for various inflammatory markers (interleukins, tumor necrosis factor-α, interferon-γ, and C-reactive protein [CRP]) the morning after hospital admission.
Significant differences in test performance between COVID-19 patients and controls were found only on the Continuous Performance Test, which assesses selective and continuous memory in a measure with three levels of difficulty. COVID-19 patients showed more missed responses during the test's more challenging section and more missed responses and fewer correct responses during its most challenging section. Furthermore, reaction time, except during the most challenging section, correlated positively with CRP levels measured at hospital admission.
Derya Unutmaz on the decline in antibodies post Covid-19:
Everyone needs to understand that the decline of SARS-CoV-2 Abs after the peak of infection is normal. This is basic immunology. If our immune system did not contract after viral infections, we would all be walking around with gigantic lymph nodes. SARS-CoV-2 Abs look good!
I think there are two facets to this, one is people worrying that undetectable antibodies means no immunity, and that's a misperception -- there are other components to immune memory: memory B and memory T cells, that can quickly escalate an immune response, including regenerating antibodies, to a previously encountered antigen.This seems so basic I have been wondering if I am missing something when everyone is worried about antibody levels dropping.
A protein drug may help improve the conditions of severely ill coronavirus patients, a new small study suggests.
Interleukin 7 (IL-7) immunotherapy was found to restore counts of a specific white blood cell in those critically with COVID-19, the disease caused by the virus.
The international team, led by Université Catholique de Louvain in Brussels, Belgium, says the treatment also seemed to help quell and even 'reverse' dangerous inflammation in patients.
A mutation in the protein that allows SARS-CoV-2 to enter cells might make it easier for the virus to spread — or it might not make a difference at all.
That's the crux of a debate over a mutation known as D614G, which affects the spike protein on the virus' surface. The mutation is not new. It appears in low levels in samples taken from COVID-19 patients as far back as February. But this variation of the virus (nicknamed the "G" variation) seems to show up in more and more of the virus samples taken from people infected recently compared to early in the pandemic.
This seems so basic I have been wondering if I am missing something when everyone is worried about antibody levels dropping.
Is this common in viral illnesses?
Walis said:
Impaiment acuity of the sense of taste and smell was
present in most cases and abnormal perception of various tastes
and smells was also commonly found.
Is this common in viral illnesses?
I didn't know on which of the many threads to say this, but this is as good as any.
It may, or may not, be worth pointing out that whatever it was that caused the Dalston outbreak of ME in 1955, which was considered similar in many respects to the Royal Free, it apparently affected the sense of taste and smell in a similar, but perhaps not identical way to Covid.
Walis said:
Impaiment acuity of the sense of taste and smell was
present in most cases and abnormal perception of various tastes
and smells was also commonly found.
Is this common in viral illnesses?
Researchers have identified a potent cocktail of antibodies that may help doctors treat Covid-19 infections and protect people at risk from falling ill with the disease.
The antibodies were collected from patients hospitalised with severe Covid-19, and they could be manufactured at scale by pharmaceutical firms and transfused into the blood to fight the virus or prevent it from taking hold.
“We specifically isolated very potent antibodies that can be mass produced and then administered,” Ho said. “We would assume that these could be used to prevent or treat Sars-Cov-2. We’d be looking to treat early in the course of infection, particularly those at risk of developing severe disease such as the elderly and those with underlying illness.”
Does anyone know exactly how these monoclonal antibodies are manufactured? Do they contain mouse protein, and would it be a problem if they did?
Antibody Expression and Purification
For each antibody, variable genes were optimized for human cell expression and synthesized by GenScript. VH and VL were inserted separately into plasmids (gWiz or pcDNA3.4) that encode the constant region for H chain and L chain. Monoclonal antibodies were expressed in Expi293 (ThermoFisher, A14527) by co-transfection of H chain and L chain expressing plasmids using polyethylenimine and culture in 37 °C shaker at 125 RPM and 8% CO2. On day 3 post transfection, 400 μL of supernatant were collected for screening for binding to S trimer and RBD by ELISA, and for neutralization of SARS-CoV-2 pseudovirus and authentic virus. Supernatants were also collected on day 5 for antibody purification by rProtein A Sepharose (GE, 17-1279-01) affinity chromatography.